Evidence map›Paper›PMID 36895292›Full record

ArticleJournal of hematology2023

The Impact of Graft CD3

Khalid Halahleh, Rawan Mustafa, Dania Sarhan, Dalia Al Rimawi, Hadeel Abdelkhaleq, Isra Muradi, Iyad Sultan

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Khalid HalahlehHematology Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan.
Rawan MustafaDepartment of Internal Medicine, Hematology Oncology Section, King Hussein Cancer Center, Amman, Jordan.
Dania SarhanCell Therapy and Applied Genomics (CTAG Lab) laboratory, King Hussein Cancer Center, Amman, Jordan.
Dalia Al RimawiBiostatistics Unit, Research Office, King Hussein Cancer Center, Amman, Jordan.
Hadeel AbdelkhaleqBiostatistics Unit, Research Office, King Hussein Cancer Center, Amman, Jordan.
Isra MuradiDepartment of Internal Medicine, University of Tripoli, Tripoli, Libya Jamahiriya.
Iyad SultanDepartment of Pediatrics, Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan.
King Hussein Cancer Center · JOUniversity of Tripoli · LY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data on whether the graft CD3-positive (CD3 Methods: Using King Hussein Cancer Center (KHCC) Blood and Marrow Transplantation (BMT) Registry database, 52 adult subjects, receiving the first T-cell-replete HLA-mismatched allogeneic hematopoietic PBSCT for acute leukemias or myelodysplastic syndrome, were identified, from January 2017 to December 2020. The cutoff value of graft CD3 Results: Subject covariates were displayed. Subject's characteristics were comparable, except for higher nucleated cells and more female donors in the high CD3 Conclusions: Our data suggest that high graft CD3

Indexed as

Allogeneic hematopoietic cell transplantationGraft CD3+ T-cell doseGvHDOverall survivalPBSCRelapse-free survival

Identifiers

PMID36895292
PMCPMC9990716
OpenAlexW4321850956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.